title: [Effects of rilmenidine on rats made insulin resistant and hypertensive by a high fructose diet].
abstract: This study was aimed to determine the effects of rilmenidine, an hypertensive drug, in an animal model of hypertension associated with insulin resistance, i.e. rats fed on a high fructose diet. Wistar rats were fed during four weeks either on a standard diet (S) or on a high fructose diet (F, 34.5% de fructose). In half of the F groups, rilmenidine (1 mg/kg/day) was added to the drinking water during the two last weeks of the diet (FR). Arterial blood pressure as well as insulin efficiency were determined at the end of the four weeks. Body weight gain was higher in F than in S rats (66 +/- 8 g versus 45 +/- 8 g; p < 0.05), this was prevented by rilmenidine treatment (32 +/- 2 g). Arterial systolic blood pressure was increased in F rats (162 +/- 2 vs 155 +/- 2 mmHg; p < 0.05), rilmenidine brought this value back to normal (149 +/- 3 mmHg). During the euglycemic hyperinsulinemic clamp, glucose utilization was lower (10 +/- 1 vs 14 +/- 1.5 mg/min/kg; p < 0.05) and hepatic glucose production higher (1 +/- 0.01 vs 0 mg/min/kg; p < 0.01) in F than in S rats. These changes in insulin action were totally abolished by rilmenidine. These data demonstrate that rilmenidine can ameliorate the deleterious effects of a high fructose diet, i.e. weight gain, hypertension and resistance to the effects of insulin Rilmenidine could represent a potential therapeutic agent for the treatment of hypertension associated with metabolic disorders such as syndrom X and obesity.
authors.affiliation: Laboratoire de physiopathologie de la nutrition, CNRS URA 307, université Denis-Diderot, Paris.
authors.forename: M F
authors.initials: MF
authors.lastname: Berthault
authors.forename: J
authors.initials: J
authors.lastname: Morin
authors.forename: M
authors.initials: M
authors.lastname: Dubar
authors.forename: A
authors.initials: A
authors.lastname: Ktorza
authors.forename: P
authors.initials: P
authors.lastname: Ferré
authors.forename: L
authors.initials: L
authors.lastname: Pénicaud
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy*; D004040:Dietary Carbohydrates / Q000008:administration & dosage / Q000009:adverse effects; D004195:Disease Models, Animal; D005632:Fructose; D006973:Hypertension / Q000139:chemically induced / Q000188:drug therapy*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D010080:Oxazoles / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D000077769:Rilmenidine
chemical_list: D000316:Adrenergic alpha-Agonists; D000959:Antihypertensive Agents; D001786:Blood Glucose; D004040:Dietary Carbohydrates; D007328:Insulin; D010080:Oxazoles; D005632:Fructose; D000077769:Rilmenidine
vernacular_title: Effets de la rilménidine chez le rat rendu insulinorésistant et hypertendu par un régime riche en fructose.